Cargando…
Dianthin and Its Potential in Targeted Tumor Therapies
Dianthin enzymes belong to ribosome-inactivating proteins (RIPs) of type 1, i.e., they only consist of a catalytic domain and do not have a cell binding moiety. Dianthin-30 is very similar to saporin-S3 and saporin-S6, two RIPs often used to design targeted toxins for tumor therapy and already teste...
Autor principal: | Fuchs, Hendrik |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6832487/ https://www.ncbi.nlm.nih.gov/pubmed/31614697 http://dx.doi.org/10.3390/toxins11100592 |
Ejemplares similares
-
Magnetic Nanoparticle-Based Dianthin Targeting for Controlled Drug Release Using the Endosomal Escape Enhancer SO1861
por: Zarinwall, Ajmal, et al.
Publicado: (2021) -
Targeted dianthin is a powerful toxin to treat pancreatic carcinoma when applied in combination with the glycosylated triterpene SO1861
por: Bhargava, Cheenu, et al.
Publicado: (2017) -
Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861
por: Panjideh, Hossein, et al.
Publicado: (2022) -
Correction: Panjideh et al. Improved Therapy of B-Cell Non-Hodgkin Lymphoma by Obinutuzumab-Dianthin Conjugates in Combination with the Endosomal Escape Enhancer SO1861. Toxins 2022, 14, 478
por: Panjideh, Hossein, et al.
Publicado: (2022) -
Glycosylated Triterpenoids as Endosomal Escape Enhancers in Targeted Tumor Therapies
por: Fuchs, Hendrik, et al.
Publicado: (2017)